vials of compounded semaglutide SkinnyRx: Injectable Semaglutide (GLP-1)
Description
FDA approved Dec 2025.
Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats of the blockbuster drugs.
Research shows that nearly 90% of people with type 2 diabetes also struggle with their weight, and these medications solve both problems at once
Combining GLP-1 medications with ketogenic diets raises important questions about safety and metabolic outcomes
Two 131-patient cohorts with balanced baseline characteristics were formed by propensity score matching
A budget-first approach to expanding preventative weight health benefits without health plan shock.
